Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies (Q34443923)

2 August 2017

1 reference

title

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies (English)

1 reference

2 August 2017

1 reference

George K Philips

1

1 reference

PubMed ID

25323844

2 August 2017

Michael Atkins

series ordinal

2

1 reference

2 August 2017

16 October 2014

1 reference

2 August 2017

International Immunology

1 reference

2 August 2017

27

1 reference

2 August 2017

39-46

1 reference

2 August 2017

1

1 reference

Hallmarks of Cancer: The Next Generation

2 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Structure and chromosomal localization of the human PD-1 gene (PDCD1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU095

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1093/INTIMM/DXU095

1 reference

2 August 2017

1 reference

PubMed ID

25323844